Overview

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of RAD001(Everolimus) and the highest dose of this drug that can be given to people safely. RAD001(Everolimus) is a drug that works by preventing cells in the body from growing and dividing. Information from basic and Phase I clinical research studies suggests that RAD001 also may help to prevent tumor growth in people with relapsed or refractory lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital
Novartis
Treatments:
Everolimus
Sirolimus